North East and North Cumbria
ICS Formulary
 
back
4 Central nervous system
04-07-01 Non-opioid analgesics and compound analgesic preparations

Paracetamol
First Choice
  • Paracetamol 500mg tablets / soluble tablets
  • Paracetamol 1gram injection for IV infusion Red 
    • NoTGhdNC: approved for limited short-term use where oral and rectal routes cannot be used and NSAIDs are not appropriate in paediatric areas only, the 50ml formulation should be stocked.
  • Paracetamol suppositories
  • Licensed preparations include 60mg,125mg, 250mg, and 500mg suppositories are available in primary care.
  • unlicensed unlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.

Green View adult BNF  View SPC online  View childrens BNF
Naproxen tablets
Formulary
Link  MHRA Drug Safety Update (June 2023): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy

Green View adult BNF  View SPC online  View childrens BNF
Ibuprofen
Formulary
Link  MHRA Drug Safety Update (June 2015): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk
Link  MHRA Drug Safety Update (June 2023): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy

Green View adult BNF  View SPC online  View childrens BNF
Aspirin
Formulary

Green View adult BNF  View SPC online  View childrens BNF
Diclofenac
Formulary
  • Oral diclofenac is restricted to short-term use for post operative pain.
  • If long-term use is required diclofenac is only approved for 4th line treatment (see below):
    • Ibuprofen low dose – first line treatment.
    • Naproxen low dose – second line treatment.
    • Naproxen high dose – third line treatment.
    • Diclofenac – fourth line treatment.
Link  MHRA Drug Safety Update (Dec 2007): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks
Link  MHRA Drug Safety Update (Jan 2015): Cox-2 selective inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs): Cardiovascular safety.
Link  MHRA Drug Safety Update (June 2013): Diclofenac: new contraindications and warnings
Link  MHRA Drug Safety Update (June 2023): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy
Link  MHRA Drug Safety Update (Oct 2012): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks

Green plus View adult BNF  View SPC online  View childrens BNF